See more : Saudi Cement Company (3030.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Amgen Inc. (AMG.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amgen Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Darshan Orna Limited (DARSHANORNA.BO) Income Statement Analysis – Financial Results
- Khaitan Chemicals and Fertilizers Limited (KHAICHEM.BO) Income Statement Analysis – Financial Results
- United Palm Oil Industry Public Company Limited (UPOIC.BK) Income Statement Analysis – Financial Results
- Parkway Corporate Limited (PWN.AX) Income Statement Analysis – Financial Results
- Green Landscaping Group AB (publ) (GREEN.ST) Income Statement Analysis – Financial Results
Amgen Inc. (AMG.DE)
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.19B | 26.32B | 25.98B | 25.42B | 23.36B | 23.75B | 22.85B | 22.99B | 21.66B | 20.06B | 18.68B | 17.27B | 15.58B | 15.05B | 14.64B | 15.00B | 14.77B | 14.27B | 12.43B | 10.55B | 8.36B | 5.52B | 4.02B | 3.45B | 3.20B | 2.64B | 2.35B | 2.20B | 1.90B | 1.62B | 1.35B | 1.08B | 679.80M | 381.20M | 190.40M | 70.20M | 44.30M | 29.80M | 21.10M |
| Cost of Revenue | 8.42B | 6.41B | 6.45B | 6.16B | 4.36B | 4.10B | 4.07B | 4.16B | 4.23B | 4.42B | 3.35B | 2.92B | 2.43B | 2.22B | 2.09B | 2.30B | 2.55B | 2.10B | 2.08B | 1.73B | 1.34B | 735.70M | 443.00M | 196.60M | 225.30M | 201.40M | 183.70M | 182.90M | 188.70M | 163.60M | 169.30M | 151.20M | 91.20M | 55.20M | 14.70M | 44.00M | 35.50M | 21.80M | -2.50M |
| Gross Profit | 19.78B | 19.92B | 19.53B | 19.27B | 19.01B | 19.65B | 18.78B | 18.83B | 17.44B | 15.64B | 15.33B | 14.35B | 13.16B | 12.83B | 12.55B | 12.71B | 12.22B | 12.17B | 10.35B | 8.82B | 7.02B | 4.79B | 3.57B | 3.25B | 2.98B | 2.44B | 2.16B | 2.02B | 1.72B | 1.46B | 1.19B | 929.10M | 588.60M | 326.00M | 175.70M | 26.20M | 8.80M | 8.00M | 23.60M |
| Gross Profit Ratio | 70.15% | 75.66% | 75.16% | 75.77% | 81.35% | 82.73% | 82.19% | 81.90% | 80.49% | 77.96% | 82.08% | 83.10% | 84.42% | 85.25% | 85.72% | 84.70% | 82.75% | 85.32% | 83.25% | 83.59% | 83.96% | 86.68% | 88.97% | 94.30% | 92.97% | 92.38% | 92.17% | 91.68% | 90.09% | 89.90% | 87.50% | 86.00% | 86.58% | 85.52% | 92.28% | 37.32% | 19.86% | 26.85% | 111.85% |
| Research & Development | 4.78B | 4.43B | 4.82B | 4.21B | 4.12B | 3.74B | 3.56B | 3.84B | 4.07B | 4.30B | 4.08B | 3.38B | 3.17B | 2.89B | 2.86B | 3.03B | 3.27B | 3.37B | 2.31B | 2.03B | 1.66B | 1.12B | 865.00M | 845.00M | 822.80M | 663.30M | 630.80M | 528.30M | 451.70M | 323.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.52B | 4.57B | 4.53B | 4.77B | 4.36B | 5.33B | 4.87B | 5.06B | 4.85B | 4.70B | 5.18B | 4.80B | 4.49B | 3.98B | 3.82B | 3.79B | 3.36B | 3.37B | 2.79B | 2.56B | 1.95B | 1.46B | 970.70M | 826.90M | 654.30M | 515.40M | 483.80M | 470.60M | 418.40M | 359.80M | 583.70M | 397.40M | 0.00 | 0.00 | 134.60M | 23.00M | 10.30M | 6.80M | 22.00M |
| Selling & Marketing | 647.00M | 841.00M | 843.00M | 962.00M | 789.00M | 674.00M | 620.00M | 489.00M | 346.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.18B | 5.41B | 5.37B | 5.73B | 5.15B | 5.33B | 4.87B | 5.06B | 4.85B | 4.70B | 5.18B | 4.80B | 4.49B | 3.98B | 3.82B | 3.79B | 3.36B | 3.37B | 2.79B | 2.56B | 1.95B | 1.46B | 970.70M | 826.90M | 654.30M | 515.40M | 483.80M | 470.60M | 418.40M | 359.80M | 583.70M | 397.40M | 443.70M | 257.20M | 134.60M | 23.00M | 10.30M | 6.80M | 22.00M |
| Other Expenses | 915.00M | 503.00M | 194.00M | 189.00M | 66.00M | 314.00M | 375.00M | 133.00M | 49.00M | 454.00M | 196.00M | 589.00M | 294.00M | 411.00M | 361.00M | 674.00M | 817.00M | 370.00M | 396.00M | 333.00M | 316.10M | -7.09B | 205.80M | 211.80M | 176.80M | 143.80M | 117.10M | 100.30M | 84.20M | 74.50M | 50.70M | 33.60M | 21.50M | 0.00 | 12.00M | 8.00M | 4.10M | 2.60M | 2.50M |
| Operating Expenses | 11.88B | 10.35B | 10.38B | 10.13B | 9.33B | 9.38B | 8.81B | 9.04B | 8.97B | 9.45B | 9.46B | 8.77B | 8.84B | 7.29B | 7.05B | 7.49B | 7.44B | 7.10B | 5.50B | 4.92B | 3.92B | -4.51B | 2.04B | 1.88B | 1.65B | 1.32B | 1.23B | 1.10B | 954.30M | 757.90M | 634.40M | 431.00M | 465.20M | 274.90M | 146.60M | 31.00M | 14.40M | 9.40M | 24.50M |
| Cost & Expenses | 20.29B | 16.76B | 16.84B | 16.29B | 13.69B | 13.48B | 12.88B | 13.20B | 13.19B | 13.87B | 12.81B | 11.69B | 11.27B | 9.51B | 9.14B | 9.79B | 9.99B | 9.20B | 7.58B | 6.65B | 5.26B | -3.78B | 2.48B | 2.08B | 1.88B | 1.52B | 1.42B | 1.28B | 1.14B | 921.50M | 803.70M | 582.20M | 556.40M | 330.10M | 161.30M | 75.00M | 49.90M | 31.20M | 22.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 256.00M | 753.00M | 674.00M | 928.00M | 629.00M | 603.00M | 465.00M | 420.00M | 485.00M | 448.00M | 376.00M | 276.00M | 352.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.88B | 1.41B | 1.20B | 1.26B | 1.29B | 1.39B | 1.30B | 1.26B | 1.10B | 1.07B | 1.02B | 1.05B | 610.00M | 604.00M | 578.00M | 344.00M | 2.14B | 2.28B | 29.00M | 1.06B | 0.00 | 12.83B | 0.00 | 0.00 | 0.00 | 0.00 | 134.10M | 0.00 | 0.00 | 208.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.07B | 3.42B | 3.40B | 3.60B | 2.21B | 1.95B | 1.96B | 2.11B | 2.11B | 2.09B | 1.29B | 294.00M | 294.00M | 294.00M | 294.00M | 1.07B | 1.20B | 963.00M | 841.00M | 734.00M | 686.50M | 447.30M | 265.90M | 211.80M | 176.80M | 143.80M | 117.10M | 100.30M | 84.20M | 74.50M | 50.70M | 33.60M | 21.50M | 17.70M | 12.00M | 8.00M | 4.10M | 2.60M | 2.50M |
| EBITDA | 14.80B | 13.49B | 12.54B | 12.93B | 12.63B | 12.88B | 12.86B | 11.94B | 11.18B | 8.75B | 7.39B | 6.36B | 5.05B | 6.22B | 6.08B | 6.64B | 5.98B | 6.03B | 5.69B | 4.64B | 3.78B | 2.65B | 1.80B | 1.58B | 1.50B | 1.26B | 1.05B | 1.02B | 845.00M | 773.00M | 601.90M | 531.70M | 144.90M | 68.80M | 41.10M | 3.20M | -1.50M | 1.20M | 1.60M |
| EBITDA Ratio | 52.50% | 33.25% | 36.19% | 36.95% | 44.63% | 46.06% | 47.71% | 45.34% | 41.88% | 33.18% | 33.66% | 36.81% | 32.43% | 41.29% | 41.50% | 44.44% | 49.41% | 50.92% | 46.16% | 49.19% | 44.97% | 228.08% | 43.58% | 40.71% | 41.62% | 43.38% | 47.43% | 43.85% | 41.82% | 53.78% | 40.93% | 43.19% | 16.03% | 11.91% | 19.70% | 7.55% | -21.44% | -6.04% | 14.69% |
| Operating Income | 7.90B | 5.34B | 6.01B | 5.79B | 9.67B | 10.26B | 9.97B | 9.79B | 8.47B | 6.19B | 5.87B | 5.58B | 4.31B | 5.55B | 5.51B | 5.21B | 3.98B | 3.84B | 4.85B | 3.35B | 3.09B | 6.31B | 1.53B | 1.37B | 1.33B | 1.12B | 930.30M | 916.00M | 760.80M | 698.50M | 551.20M | 498.10M | 123.40M | 51.10M | 29.10M | -4.80M | -5.60M | -1.40M | -900.00K |
| Operating Income Ratio | 28.01% | 20.27% | 23.11% | 22.79% | 41.41% | 43.22% | 43.65% | 42.60% | 39.10% | 30.86% | 31.41% | 32.30% | 27.67% | 36.84% | 37.60% | 34.75% | 26.94% | 26.91% | 39.00% | 31.73% | 36.99% | 114.20% | 38.13% | 39.67% | 41.35% | 42.33% | 39.66% | 41.67% | 39.96% | 43.12% | 40.68% | 46.11% | 18.15% | 13.41% | 15.28% | -6.84% | -12.64% | -4.70% | -4.27% |
| Total Other Income/Expenses | -42.00M | 2.01B | -938.00M | -1.01B | -536.00M | -718.00M | -376.00M | -631.00M | -492.00M | -606.00M | -602.00M | -568.00M | -162.00M | -228.00M | -302.00M | -199.00M | -19.00M | 180.00M | 20.00M | 47.00M | 81.80M | -6.99B | 155.10M | 306.20M | 241.20M | 106.00M | -68.90M | 46.30M | 33.60M | -110.20M | 41.20M | 65.00M | 34.60M | 21.30M | 300.00K | -2.60M | 7.60M | 3.00M | 1.50M |
| Income Before Tax | 7.86B | 7.35B | 6.70B | 8.13B | 9.14B | 9.55B | 9.60B | 9.16B | 7.98B | 5.59B | 5.27B | 5.01B | 4.15B | 5.32B | 5.20B | 5.25B | 3.96B | 4.02B | 4.87B | 3.40B | 3.17B | -684.50M | 1.69B | 1.67B | 1.57B | 1.22B | 861.40M | 962.30M | 794.40M | 588.30M | 592.40M | 563.10M | 158.00M | 72.40M | 29.40M | -7.40M | 2.00M | 1.60M | 600.00K |
| Income Before Tax Ratio | 27.86% | 27.91% | 25.79% | 31.99% | 39.11% | 40.19% | 42.00% | 39.85% | 36.83% | 27.84% | 28.19% | 29.01% | 26.63% | 35.32% | 35.54% | 34.99% | 26.82% | 28.17% | 39.16% | 32.18% | 37.97% | -12.39% | 41.99% | 48.55% | 48.88% | 46.34% | 36.72% | 43.78% | 41.73% | 36.31% | 43.72% | 52.12% | 23.24% | 18.99% | 15.44% | -10.54% | 4.51% | 5.37% | 2.84% |
| Income Tax Expense | 1.14B | 794.00M | 808.00M | 869.00M | 1.30B | 1.15B | 7.62B | 1.44B | 1.04B | 427.00M | 184.00M | 664.00M | 467.00M | 690.00M | 599.00M | 1.05B | 795.00M | 1.07B | 1.19B | 1.03B | 913.60M | 707.40M | 566.60M | 535.80M | 469.80M | 361.20M | 217.10M | 282.50M | 256.70M | 268.60M | 217.80M | 205.50M | 60.10M | 38.10M | 10.30M | 800.00K | 300.00K | 800.00K | 100.00K |
| Net Income | 6.72B | 6.55B | 5.89B | 7.26B | 7.84B | 8.39B | 1.98B | 7.72B | 6.94B | 5.16B | 5.08B | 4.35B | 3.68B | 4.63B | 4.61B | 4.20B | 3.17B | 2.95B | 3.67B | 2.36B | 2.26B | -1.39B | 1.12B | 1.14B | 1.10B | 863.20M | 644.30M | 679.80M | 537.70M | 319.70M | 383.30M | 357.60M | 97.90M | 34.30M | 19.10M | -8.20M | 1.70M | 800.00K | 500.00K |
| Net Income Ratio | 23.83% | 24.89% | 22.68% | 28.57% | 33.57% | 35.35% | 8.66% | 33.59% | 32.03% | 25.71% | 27.21% | 25.17% | 23.64% | 30.74% | 31.45% | 27.97% | 21.43% | 20.68% | 29.56% | 22.40% | 27.04% | -25.20% | 27.88% | 33.02% | 34.22% | 32.67% | 27.47% | 30.93% | 28.24% | 19.73% | 28.29% | 33.10% | 14.40% | 9.00% | 10.03% | -11.68% | 3.84% | 2.68% | 2.37% |
| EPS | 12.49 | 12.18 | 10.34 | 12.40 | 12.96 | 12.70 | 2.71 | 10.32 | 9.15 | 6.80 | 6.75 | 5.61 | 4.07 | 4.82 | 4.53 | 3.79 | 2.83 | 2.51 | 2.97 | 1.86 | 1.75 | -1.21 | 1.07 | 1.11 | 1.07 | 0.85 | 0.61 | 0.61 | 0.48 | 0.29 | 0.35 | 0.31 | 0.09 | 0.04 | 0.03 | -0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 | 12.62 | 2.69 | 10.24 | 9.06 | 6.70 | 6.64 | 5.52 | 4.04 | 4.79 | 4.51 | 3.77 | 2.82 | 2.48 | 2.93 | 1.81 | 1.69 | -1.21 | 1.03 | 1.05 | 1.02 | 0.82 | 0.59 | 0.61 | 0.47 | 0.28 | 0.35 | 0.31 | 0.09 | 0.03 | 0.03 | -0.01 | 0.01 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 537.79M | 538.00M | 570.00M | 586.00M | 605.00M | 661.00M | 731.00M | 748.00M | 758.00M | 759.00M | 753.00M | 775.00M | 905.00M | 960.00M | 1.02B | 1.07B | 1.12B | 1.18B | 1.24B | 1.27B | 1.29B | 1.15B | 1.05B | 1.03B | 1.02B | 1.02B | 1.06B | 1.12B | 1.12B | 1.12B | 1.10B | 1.15B | 1.09B | 857.50M | 636.67M | 820.00M | 940.86M | 940.86M | 940.86M |
| Weighted Avg Shares Out (Dil) | 538.00M | 541.00M | 573.00M | 590.00M | 609.00M | 665.00M | 735.00M | 754.00M | 766.00M | 770.00M | 765.00M | 787.00M | 912.00M | 965.00M | 1.02B | 1.08B | 1.12B | 1.19B | 1.26B | 1.32B | 1.35B | 1.15B | 1.08B | 1.08B | 1.08B | 1.06B | 1.10B | 1.12B | 1.14B | 1.13B | 1.10B | 1.15B | 1.09B | 1.14B | 636.67M | 820.00M | 940.86M | 940.86M | 940.86M |
Source: https://incomestatements.info
Category: Stock Reports